Signal Desk · Markets

Summit shares drop after FDA rejects lung cancer drug

2026-11-16 · 1 source · Economic Times Markets

In short

Summit Therapeutics shares dropped after the US FDA declined to approve its lung cancer drug ivonescimab. The agency cited weak overall survival benefits from late-stage trials, while Summit pointed to differences in regional survival results.

What the reporting says

Summit Therapeutics shares fell after the US FDA declined to approve ivonescimab for lung cancer. The regulator pointed to insufficient overall survival benefits from late-stage trials, even as Summit highlighted regional survival differences. The decision has raised analyst concerns about possible effects on similar drugs in development, while investors await new trial results comparing ivonescimab with standard lung cancer therapies.

Why it matters

Summit Therapeutics shares fell after the US FDA declined to approve ivonescimab for lung cancer, citing insufficient overall survival benefits from late-stage trials. Summit pointed to regional survival differences, but investors and analysts are focused on the FDA decision’s possible impact on similar treatments in development. The next catalyst is more trial data comparing ivonescimab with standard therapies.

Touches: Summit Therapeutics, Healthcare, Markets

Sources